Journal Scans
Phase 1 and Pharmacokinetic Study of Bolus-Infusion Flavopiridol Followed by Cytosine Arabinoside and Mitoxantrone for Acute Leukemias
Hybrid FLAM Promising for Adult Leukemia
JE Karp, BD Smith, LS Resar, JM Greer, A Blackford, M Zhao, D Moton-Nelson, K Alino, MJ Levis, SD Gore, B Joseph, H Carraway, MA McDevitt, L Bagain, K Mackey, J Briel, LA Doyle, JJ Wright, MA Rudek
Yes
20110224
2011 Mar 24
Blood
Yes
Phase 1 and Pharmacokinetic Study of Bolus-Infusion Flavopiridol Followed by Cytosine Arabinoside and Mitoxantrone for Acute Leukemias
Blood. 2011 Mar 24;117(12):3302-3310, JE Karp, BD Smith, LS Resar, JM Greer, A Blackford, M Zhao, D Moton-Nelson, K Alino, MJ Levis, SD Gore, B Joseph, H Carraway, MA McDevitt, L Bagain, K Mackey, J Briel, LA Doyle, JJ Wright, MA Rudek
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
Abstract
Flavopiridol is a protein bound, cytotoxic, cyclin-dependent kinase inhibitor. Flavopiridol given by 1-hour bolus at 50 mg/m2 daily 3 times followed by cytosine arabinoside and mitoxantrone (FLAM) is active in adults with poor-risk acute leukemias. A pharmacologically derived “hybrid” schedule (30-minute bolus followed by 4-hour infusion) of flavopiridol was more effective than bolus administration in refractory chronic lymphocytic leukemia. Our phase 1 trial “hybrid FLAM” in 55 adults with relapsed/refractory...
